Antios Therapeutics is a clinical-stage biopharmaceutical company focused on developing an oral drug candidate aimed at providing a potentially curative treatment for hepatitis B virus (HBV) infections. The company leverages its experienced leadership team to advance therapies that address the significant unmet medical need for effective HBV management.
Funding
$75M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ECGGFounders
Product
Problem
Hepatitis B virus (HBV) infections represent a significant unmet medical need, requiring more effective and potentially curative treatments. Current therapies often fail to provide a complete cure, leading to chronic infections and long-term health complications.
Solution
Antios Therapeutics is a biopharmaceutical company developing an oral drug candidate designed to provide a potentially curative treatment for chronic HBV infections. The company's approach focuses on advancing therapies that directly target the virus, aiming to achieve a complete and sustained viral remission. By addressing the limitations of existing treatments, Antios Therapeutics seeks to offer a more effective solution for patients suffering from HBV. The oral administration route enhances patient convenience and adherence, potentially improving treatment outcomes.
Target Audience
The primary target audience includes individuals infected with chronic Hepatitis B virus (HBV) requiring effective therapeutic intervention.
Features
- Oral drug candidate for the treatment of HBV infections
- Focus on achieving a complete and sustained viral remission
- Targets the virus directly to eliminate chronic infections